EdiGENE, a Japanese biotechnology firm that develops CRISPR-based therapies, has raised ¥1.6 billion ($14.4 million) in its Series B funding round led by UTokyo Innovation Platform, the University of Tokyo’s investment arm for innovations and startups.
Start your deal-making journey now!
Subscribe now to enjoy unlimited access at just $59.
Premium coverage on private equity, venture capital, and startups in Asia.
Exclusive scoops from our reporters in nine key markets.
In-depth interviews with industry leaders shaping the ecosystem.
Already a Subscriber? Log in
Contact us for corporate subscriptions at subs@dealstreetasia.com
